Literature DB >> 18569696

Stimulatory effect of Ceriops tagal on hexose uptake in L6 muscle cells in culture.

Akhilesh Kumar Tamrakar1, Rajesh Kumar, Ramesh Sharma, Anil Kumar Balapure, Vijai Lakshmi, Arvind Kumar Srivastava.   

Abstract

The ethanolic extracts of a mangrove plant Ceriops tagal (Family Rhizophoraceae) and its sequential fractions thereof were studied for their effect on 3H-2-deoxyglucose uptake by L6 rat muscle cells cultured to the myotube stage. Among these, the n-hexane soluble fraction of ethanolic extract of the leaves of C. tagal enhanced 3H-2-deoxyglucose uptake even at 2 microg mL(-1) concentration with half maximum activity at 10 microg mL(-1), comparable with insulin (1 microM) and metformin (400 microM). This enhancement in glucose uptake was found to be insulin independent and in contrast to insulin, its effect was also prevalent in undifferentiated myoblasts. It may be concluded from the results that n-hexane soluble fraction of ethanolic extract of C. tagal have the property to stimulate the glucose uptake, which might be a useful source for the isolation of new antihyperglycemic compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18569696     DOI: 10.1080/14786410701592885

Source DB:  PubMed          Journal:  Nat Prod Res        ISSN: 1478-6419            Impact factor:   2.861


  2 in total

1.  Acute and subchronic antihyperglycemic activities of Bowdichia virgilioides roots in non-diabetic and diabetic rats.

Authors:  Ana Carolina Mazei Silva; Maísa Pavani Dos Santos; Suélem Aparecida de França; Virginia Claudia da Silva; Luiz Everson da Silva; Uir Santana de Figueiredo; Evandro Luiz Dall'Oglio; Paulo Teixeira de Sousa Júnior; Carbene França Lopes; Amanda Martins Baviera; Nair Honda Kawashita
Journal:  J Intercult Ethnopharmacol       Date:  2014-11-28

Review 2.  A Review on Antidiabetic Properties of Indian Mangrove Plants with Reference to Island Ecosystem.

Authors:  V Sachithanandam; P Lalitha; A Parthiban; T Mageswaran; K Manmadhan; R Sridhar
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-05       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.